|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
CA1271477A
(en)
|
1983-11-18 |
1990-07-10 |
John F. Gerster |
1h-imidazo[4,5-c]quinolin-4-amines
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
US6608201B2
(en)
|
1992-08-28 |
2003-08-19 |
3M Innovative Properties Company |
Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
|
UA67760C2
(ru)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Имидазонафтиридины и их применение для индуцирования биосинтеза цитокинов
|
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
KR20020012292A
(ko)
|
1999-06-25 |
2002-02-15 |
제넨테크, 인크. |
항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
|
|
US6635677B2
(en)
|
1999-08-13 |
2003-10-21 |
Case Western Reserve University |
Methoxyamine combinations in the treatment of cancer
|
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
UA74593C2
(en)
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
|
UA74852C2
(en)
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
AU2006216669A1
(en)
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
CA2462203A1
(en)
|
2001-10-12 |
2003-11-20 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
|
EP1455700A4
(en)
|
2001-11-16 |
2007-02-14 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
|
|
HRP20040541A2
(en)
|
2001-11-27 |
2004-10-31 |
Anadys Pharmaceuticals |
3- -D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
EP2206517B1
(en)
|
2002-07-03 |
2023-08-02 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions comprising anti-PD-L1 antibodies
|
|
EP1413316A1
(en)
|
2002-09-27 |
2004-04-28 |
Bruno Robert |
Bifunctional conjugates or fusion proteins
|
|
US7091214B2
(en)
|
2002-12-20 |
2006-08-15 |
3M Innovative Properties Co. |
Aryl substituted Imidazoquinolines
|
|
EP1576014B1
(en)
|
2002-12-23 |
2011-06-29 |
Wyeth LLC |
Antibodies against pd-1 and uses thereof
|
|
CA2512672A1
(en)
|
2003-01-09 |
2004-07-29 |
Arizeke Pharmaceuticals Inc. |
Methods of treating lung diseases
|
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
|
EP1592302A4
(en)
|
2003-02-13 |
2007-04-25 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
|
|
WO2005025583A2
(en)
|
2003-09-05 |
2005-03-24 |
Anadys Pharmaceuticals, Inc. |
Tlr7 ligands for the treatment of hepatitis c
|
|
CN1897948A
(zh)
*
|
2003-10-03 |
2007-01-17 |
3M创新有限公司 |
烷氧基取代的咪唑并喹啉
|
|
RU2426734C2
(ru)
|
2003-10-03 |
2011-08-20 |
Зм Инновейтив Пропертиз Компани |
Пиразолопиридины и их аналоги
|
|
KR101494056B1
(ko)
|
2003-10-03 |
2015-02-16 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
피라졸로피리딘 및 그의 유사체
|
|
WO2005034979A2
(en)
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
PL1725249T3
(pl)
|
2003-11-06 |
2014-06-30 |
Seattle Genetics Inc |
Związki monometylowaliny zdolne do sprzęgania do ligandów
|
|
EP1699398A4
(en)
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
IMPROVING THE IMMUNE RESPONSE
|
|
TWI414525B
(zh)
|
2004-03-26 |
2013-11-11 |
Dainippon Sumitomo Pharma Co |
９-取代-８-氧基腺嘌呤化合物
|
|
AU2005333126A1
(en)
|
2004-07-18 |
2006-12-21 |
Csl Limited |
Methods and compositions for inducing innate immune responses
|
|
EP1809671B1
(en)
|
2004-11-09 |
2014-07-16 |
University Of Southern California |
CpG/antibody conjugate against cancer
|
|
JP2008526765A
(ja)
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚転移の処置
|
|
CA2599151A1
(en)
|
2005-02-24 |
2006-08-31 |
Janssen Pharmaceutica N.V. |
Novel quinoline derivatives as potassium ion channel openers
|
|
WO2006108627A1
(en)
|
2005-04-14 |
2006-10-19 |
Merck Patent Gmbh |
Anti-egfr antibody therapy based on an increased copy number of the egfr gene in tumor tissues
|
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
|
CN103285392A
(zh)
|
2005-04-26 |
2013-09-11 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和其用途
|
|
CN117534755A
(zh)
|
2005-05-09 |
2024-02-09 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
NZ564592A
(en)
|
2005-07-01 |
2011-11-25 |
Medarex Inc |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
KR20080080482A
(ko)
|
2005-09-07 |
2008-09-04 |
메디뮨 엘엘씨 |
독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
|
|
ZA200803029B
(en)
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
US8138172B2
(en)
|
2006-07-05 |
2012-03-20 |
Astrazeneca Ab |
8-oxoadenine derivatives acting as modulators of TLR7
|
|
PL2061814T3
(pl)
|
2006-10-27 |
2012-10-31 |
Genentech Inc |
Przeciwciała i immunokoniugaty oraz ich zastosowanie
|
|
CN101568531B
(zh)
|
2006-12-21 |
2013-11-13 |
弗·哈夫曼-拉罗切有限公司 |
Mglur5受体拮抗剂的多晶型物
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
|
|
EP2125007B9
(en)
|
2007-02-07 |
2014-04-16 |
The Regents of The University of California |
Conjugates of synthetic tlr agonists and uses therefor
|
|
JP5400763B2
(ja)
|
2007-05-08 |
2014-01-29 |
アストラゼネカ・アクチエボラーグ |
免疫調節特性を有するイミダゾキノリン類
|
|
AU2008283802A1
(en)
|
2007-07-31 |
2009-02-05 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
|
|
GB0715428D0
(en)
|
2007-08-08 |
2007-09-19 |
Imp Innovations Ltd |
Compositions and uses thereof
|
|
EP2644192B1
(en)
|
2007-09-28 |
2017-05-10 |
Pfizer Inc |
Cancer Cell Targeting Using Nanoparticles
|
|
BRPI0822002A2
(pt)
|
2008-01-15 |
2015-10-13 |
Meda Ab |
tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina.
|
|
AU2009207287B2
(en)
|
2008-01-25 |
2014-09-11 |
Gavish-Galilee Bio Applications Ltd |
Targeting of innate immune response to tumor site
|
|
KR20100137449A
(ko)
|
2008-02-07 |
2010-12-30 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
Ｔｌｒ７ 활성화제를 사용한 방광 질환의 치료
|
|
CN104873980B
(zh)
|
2008-03-18 |
2019-07-19 |
健泰科生物技术公司 |
抗her2抗体-药物偶联物和化疗剂的组合，及使用方法
|
|
EP2316032A1
(en)
|
2008-08-20 |
2011-05-04 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
KR101787309B1
(ko)
|
2008-12-09 |
2017-10-18 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체의 조절제
|
|
PT2427485T
(pt)
|
2009-05-07 |
2017-03-13 |
Immunocellular Therapeutics Ltd |
Epitopos cd133
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
US20110077263A1
(en)
|
2009-09-29 |
2011-03-31 |
University Of Southern California |
Methods and Compositions of Toll-Like Receptor (TLR) Agonists
|
|
HRP20171653T1
(hr)
|
2009-11-24 |
2017-12-15 |
Medimmune Limited |
Vezna sredstva koja služe ciljano protiv b7-h1
|
|
WO2011084726A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
WO2011084725A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
CA2796571C
(en)
|
2010-04-13 |
2019-10-29 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
US20110293700A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Nanocarrier compositions with uncoupled adjuvant
|
|
EP2603235A4
(en)
|
2010-08-13 |
2014-04-09 |
Baylor Res Inst |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
|
|
ES2616449T3
(es)
|
2010-10-01 |
2017-06-13 |
Ventirx Pharmaceuticals, Inc. |
Uso terapéutico de un agonista de TLR y terapia de combinación
|
|
MX2013006392A
(es)
|
2010-12-09 |
2013-12-06 |
Genentech Inc |
Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
|
|
PL2663555T4
(pl)
|
2011-01-12 |
2017-08-31 |
Ventirx Pharmaceuticals, Inc. |
Podstawione benzoazepiny jako modulatory receptora toll-podobnego
|
|
AU2012213437B2
(en)
|
2011-02-01 |
2016-08-18 |
Genmab A/S |
Human antibodies and antibody-drug conjugates against CD74
|
|
US20120231023A1
(en)
|
2011-03-08 |
2012-09-13 |
Baylor Research Institute |
Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
|
|
MX338353B
(es)
|
2011-04-20 |
2016-04-13 |
Medimmune Llc |
Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
|
|
UY34032A
(es)
*
|
2011-04-21 |
2012-11-30 |
Origenis Gmbh |
Nuevos inhibidores de quinasa
|
|
US9499535B2
(en)
*
|
2011-04-21 |
2016-11-22 |
Origenis Gmbh |
Kinase inhibitors
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
WO2013014668A1
(en)
|
2011-07-24 |
2013-01-31 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
TR201820873T4
(tr)
|
2011-08-01 |
2019-01-21 |
Hoffmann La Roche |
Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
|
|
WO2013022595A1
(en)
|
2011-08-11 |
2013-02-14 |
Huntsman Advanced Materials Americas Llc |
Method for producing benzoxazine compounds
|
|
CN103957939A
(zh)
|
2011-09-19 |
2014-07-30 |
约翰霍普金斯大学 |
癌症免疫治疗
|
|
US9241869B2
(en)
|
2011-10-25 |
2016-01-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
CN104661683A
(zh)
|
2011-11-09 |
2015-05-27 |
埃森德生物制药有限公司 |
免疫调节缀合物
|
|
WO2013166110A1
(en)
|
2012-05-02 |
2013-11-07 |
Yale University |
Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
|
|
AU2013263076B2
(en)
|
2012-05-15 |
2017-08-31 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
US9845356B2
(en)
|
2012-08-03 |
2017-12-19 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
|
|
DK2887959T3
(en)
|
2012-08-23 |
2019-02-18 |
Agensys Inc |
ANTIBODY-PHARMACEUTICAL CONJUGATES (ADC) BINDING TO 158P1D7 PROTEINS
|
|
US10000482B2
(en)
*
|
2012-10-19 |
2018-06-19 |
Origenis Gmbh |
Kinase inhibitors
|
|
WO2014060112A1
(en)
*
|
2012-10-19 |
2014-04-24 |
Origenis Gmbh |
Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
CN120695169A
(zh)
|
2013-12-20 |
2025-09-26 |
博德研究所 |
使用新抗原疫苗的联合疗法
|
|
EP3092255A4
(en)
|
2014-01-10 |
2017-09-20 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for treating egfr expressing tumors
|
|
CA2953507A1
(en)
|
2014-06-25 |
2015-12-30 |
Selecta Biosciences, Inc. |
Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
|
|
AU2015286043B2
(en)
|
2014-07-09 |
2020-08-20 |
Birdie Biopharmaceuticals Inc. |
Anti-PD-L1 combinations for treating tumors
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN105732635A
(zh)
|
2014-12-29 |
2016-07-06 |
南京明德新药研发股份有限公司 |
一类Toll样受体7激动剂
|
|
SG11201801365YA
(en)
|
2015-09-01 |
2018-03-28 |
Taiho Pharmaceutical Co Ltd |
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
|
|
US10821127B2
(en)
|
2015-11-09 |
2020-11-03 |
Shaperon Inc. |
Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
MX2019015744A
(es)
|
2017-06-23 |
2020-02-20 |
Birdie Biopharmaceuticals Inc |
Composiciones farmaceuticas.
|
|
AU2019335366A1
(en)
|
2018-09-07 |
2021-03-25 |
Birdie Biopharmaceuticals, Inc. |
Imidazoquinoline compounds and uses thereof
|
|
WO2020139618A1
(en)
|
2018-12-26 |
2020-07-02 |
Birdie Biopharmaceuticals, Inc. |
Immune modulatory combinations and methods for treating cancers
|
|
CN113811299A
(zh)
|
2019-03-15 |
2021-12-17 |
博笛生物科技有限公司 |
用于治疗癌症的免疫调控性组合物和方法
|
|
JP2023539625A
(ja)
|
2020-08-26 |
2023-09-15 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
Ｔｌｒアゴニストによるがんの処置
|